1. Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Issue 7 (July 2021) Authors: Chilvers, Mark A; Davies, Jane C; Milla, Carlos; Tian, Simon; Han, Zifei; Cornell, Alexandra G; Owen, Caroline A; Ratjen, Felix Journal: Lancet Issue: Volume 9:Issue 7(2021) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Issue 7 (July 2021) Authors: Flume, Patrick A; Biner, Reta Fischer; Downey, Damian G; Brown, Cynthia; Jain, Manu; Fischer, Rainald; De Boeck, Kris; Sawicki, Gregory S; Chang, Philip; Paz-Diaz, Hildegarde; Rubin, Jaime L; Yang, Yoojung; Hu, Xingdi; Pasta, David J; Millar, Stefanie J; Campbell, Daniel; Wang, Xin; Ahluwalia, Ne... Journal: Lancet Issue: Volume 9:Issue 7(2021) Page Start: 733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Issue 9 (September 2021) Authors: Hoppe, Jordana E; Chilvers, Mark; Ratjen, Felix; McNamara, John J; Owen, Caroline A; Tian, Simon; Zahigian, Rachel; Cornell, Alexandra G; McColley, Susanna A Journal: Lancet Issue: Volume 9:Issue 9(2021) Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Issue 4 (April 2019) Authors: McNamara, John J; McColley, Susanna A; Marigowda, Gautham; Liu, Fang; Tian, Simon; Owen, Caroline A; Stiles, David; Li, Chonghua; Waltz, David; Wang, Linda T; Sawicki, Gregory S Journal: Lancet Issue: Volume 7:Issue 4(2019) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. (February 2013) Authors: Kelly, Emer; Owen, Caroline A; Pinto-Plata, Victor; Celli, Bartolome R Journal: Expert review of respiratory medicine Issue: Volume 7:Number 1(2013) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. (February 2013) Authors: Kelly, Emer; Owen, Caroline A; Pinto-Plata, Victor; Celli, Bartolome R Journal: Expert review of respiratory medicine Issue: Volume 7:Number 1(2013) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. (February 2013) Authors: Kelly, Emer; Owen, Caroline A; Pinto-Plata, Victor; Celli, Bartolome R Journal: Expert review of respiratory medicine Issue: Volume 7:Number 1(2013) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗